PAK1 and viral infectious disease: Additionally, another interesting target enzyme to counteract the SARS-CoV-2 viability and progression is the major “pathogenic” kinase PAK1, whose malfunction induces inflammation, viral infection, and immuno-suppression; therefore, PAK1-blockers are considered to have an anti-coronaviral effect.